Athersys, Inc. (ATHX)

NASDAQ: ATHX · IEX Real-Time Price · USD
1.44
-0.07 (-4.64%)
Feb 1, 2023, 10:41 AM EST - Market open
-4.64%
Market Cap 25.56M
Revenue (ttm) 6.02M
Net Income (ttm) -81.24M
Shares Out 17.21M
EPS (ttm) -7.90
PE Ratio n/a
Forward PE 0.86
Dividend n/a
Ex-Dividend Date n/a
Volume 103,768
Open 1.56
Previous Close 1.51
Day's Range 1.44 - 1.56
52-Week Range 0.50 - 33.25
Beta -0.95
Analysts Sell
Price Target 3.06 (+112.5%)
Earnings Date Mar 21, 2023

About ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 104
Stock Exchange NASDAQ
Ticker Symbol ATHX
Full Company Profile

Financial Performance

In 2021, Athersys's revenue was $5.51 million, an increase of 282.92% compared to the previous year's $1.44 million. Losses were -$86.96 million, 10.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ATHX stock is "Sell." The 12-month stock price forecast is $3.06, which is an increase of 112.50% from the latest price.

Price Target
$3.06
(112.50% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Athersys to Participate in International Stroke Conference and BioProcess International

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its p...

1 day ago - Business Wire

Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in...

2 weeks ago - Business Wire

Athersys Provides MultiStem Clinical Update

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing cl...

3 weeks ago - Business Wire

Athersys Appoints Joseph Nolan to Its Board of Directors

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Jos...

3 weeks ago - Business Wire

Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and nine months ended September 30, 2022 and provided a business update.

2 months ago - Business Wire

Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.'s Biotech Conference

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in t...

2 months ago - Business Wire

Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional i...

2 months ago - Business Wire

Athersys Reschedules Third Quarter Conference Call to November 15

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it intends to file ...

2 months ago - Business Wire

Athersys, Inc. Announces Pricing of $5.5 Million Public Offering

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of co...

3 months ago - Business Wire

Athersys, Inc. Announces Proposed Public Offering

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lie...

3 months ago - Business Wire

Athersys to Host Third Quarter Financial Results Call

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results.

3 months ago - Business Wire

Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in October

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in t...

4 months ago - Business Wire

Athersys to Host Business Update Conference Call on October 6th

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business ...

4 months ago - Business Wire

Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it has entered into...

4 months ago - Business Wire

The Three Best Anti-Aging Stocks to Buy in September

Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those ...

Other symbols: LCTXUBX
4 months ago - InvestorPlace

ATHX, PETS: The Top 5 Short Squeeze Stocks to Watch This Week

Source: g0d4ather / Shutterstock.com We're starting off another week with a deep dive into the short squeeze stocks to watch! Short squeeze stocks have been popular with traders in recent months as th...

Other symbols: PETZGLSIMICSWEBR
5 months ago - InvestorPlace

Athersys Announces 1-for-25 Reverse Stock Split

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it will be executin...

5 months ago - Business Wire

Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced registered direct offering with a single healthcare-focused U.S. institutional investo...

5 months ago - Business Wire

Athersys, Inc. Announces $12 Million Registered Direct Offering

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase ...

6 months ago - Business Wire

Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second ...

6 months ago - Business Wire

Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARS--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRR...

6 months ago - Business Wire

Athersys Appoints Kasey Rosado as Interim Chief Financial Officer

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys Appoints Kasey Rosado as Interim Chief Financial Officer - Brings Operational Excellence and Financial Experience to Leadership Team

6 months ago - Business Wire

Athersys to Host Second Quarter Financial Results Call

CLEVELAND--(BUSINESS WIRE)---- $ATHX #MultiStem--Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022...

6 months ago - Business Wire

Athersys and Aspire Capital Fund Terminate Relationship

CLEVELAND--(BUSINESS WIRE)---- $ATHX--Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company co...

7 months ago - Business Wire

Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX--In connection with the Company's cost-cutting and restructuring initiatives, the Board of Directors approved reducing its size from 10 to 5 members.

8 months ago - Business Wire